Added to YB: 2025-11-18
Pitch date: 2025-11-15
PSNL [bullish]
Personalis, Inc.
+18.35%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Market Cap
$676.7M
Pitch Price
$7.41
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.03
P/E
-8.70
EV/Sales
8.22
Sector
Life Sciences Tools and Services
Category
growth
Three Healthcare Names the Market is Sleeping On - Personalis, Inc.
PSNL: Precision oncology co w/ tumor profiling & MRD testing. Secured Medicare reimbursement for MRD test - key validation. Q3 rev $14.5M (down from $25.7M), 13.2% gross margin, $21.7M net loss. $150.5M cash. 2025 outlook: $68-73M rev, 22-24% margin, ~$85M loss. $666M market cap at $7.51. MRD gaining traction, reimbursement opens adoption path.
Read full article (2 min)